Interpace Biosciences, Inc. (IDXG)

Interpace Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	40.66	40.21	31.84	41.31	32.4	24.08
Revenue Growth (YoY)	13.90%	26.31%	-22.94%	27.52%	34.55%	9.97%
Cost of Revenue	16.89	17.17	13.61	23.37	21.67	15.89
Gross Profit	23.77	23.04	18.23	17.95	10.73	8.19
Selling, General & Admin	19.82	19.6	20.1	23.74	30.02	25.66
Research & Development	0.62	0.64	0.7	1.88	2.8	2.81
Other Operating Expenses	-0.52	-0.67	1.27	4.06	4.46	3.65
Operating Expenses	20.76	20.23	22.07	29.68	37.28	32.12
Operating Income	3.01	2.81	-3.84	-11.74	-26.56	-23.93
Interest Income	-0.26	0	1.01	1.04	0.55	0.44
Interest Expense	0.97	1.01	1.01	0.92	0.55	0.44
Other Expense / Income	0.85	0.98	2	3.8	-0.41	2.73
Pretax Income	1.27	1.13	-5.84	-15.41	-26.15	-26.67
Income Tax	0.02	0.02	0.03	-0.67	0.05	-0.03
Net Income	0.92	0.8	-5.87	-14.75	-26.2	-26.64
Shares Outstanding (Basic)	4	4	4	4	4	4
Shares Outstanding (Diluted)	4	4	4	4	4	4
Shares Change	1.76%	2.97%	2.49%	2.63%	7.55%	33.03%
EPS (Basic)	0.22	0.19	-1.38	-3.57	-6.50	-7.11
EPS (Diluted)	0.21	0.18	-1.38	-3.57	-6.50	-7.11
Free Cash Flow	2.17	3.32	-8.01	-9.07	-16.15	-19.09
Free Cash Flow Per Share	0.49	0.76	-1.89	-2.19	-4.01	-5.10
Gross Margin	58.46%	57.30%	57.26%	43.44%	33.10%	34.02%
Operating Margin	7.40%	6.99%	-12.06%	-28.41%	-81.96%	-99.39%
Profit Margin	2.26%	1.99%	-18.42%	-35.69%	-80.87%	-110.63%
Free Cash Flow Margin	5.32%	8.25%	-25.17%	-21.96%	-49.86%	-79.27%
Effective Tax Rate	1.42%	1.51%	-	-	-	-
EBITDA	3.64	3.84	-3.78	-8.18	-21.63	-20.09
EBITDA Margin	8.95%	9.54%	-11.88%	-19.80%	-66.75%	-83.41%
Depreciation & Amortization	0.8	1.03	2.56	5.37	5.5	4.19
EBIT	2.84	2.81	-6.34	-13.56	-27.13	-24.27
EBIT Margin	6.97%	6.99%	-19.92%	-32.81%	-83.73%	-100.80%

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.